The fatality rate of cancer has been on a rise globally. Hence various major players in cancer stem cells are investing money and funding associated R&D activity to get a breakthrough for treatment of cancer. Existing cancer treatment studies have mostly been developed carried on animal based models, where therapies able to promote tumor shrinkage were seen effective. However, animals do not provide a complete model of progression and mechanism of human disease.
The clinical relevance of CSCs has been proven by emerging evidence, explaining that CSCs are resistant to conventional radiation treatment and chemotherapy. They are believed to be an important target for novel anti-cancer drug discovery, development of specific therapies targeted at CSCs holds hope for improvement of survival and quality of life of cancer patients, especially for patients with metastatic disease.
Top impacting factors: Market Scenario Analysis:
Pouring of funds into R&D activities and government initiatives to boost research related to cancer, successful ventures in clinical oncology, improved survival rate of patients, and increase in transplantation procedures are considered as major factors responsible for fueling growth in the cancer stem cell market. On the contrary, inequality issues coupled with diagnosis and expensive cell therapy treatments through stem cell treatment is significantly hampering the growth of cancer stem cells market. High cost cell therapies & stringent regulations reducing market growth.
Rising prevalence of cancer and increasing number of patients
According to the Cancer Research UK, around 17 million cancer cases were registered in 2018, out of which 56% of the cases were fatal. There are many key factors that may affect the success rate of chemo and radiation therapy and a person’s survival rate such as age, overall health and cancer stage. As per a research report by the World Health Organization (WHO), in low- and middle-income countries, around 70% of deaths occurs due to cancer.
Companies covered:
Merck KGaA, Bionomics,Thermo Fisher Scientific Inc., AbbVie Inc., Lonza Inc., Miltenyi Biotec, PromoCell GmbH, Stemline Therapeutics, MacroGenics, Inc., OncoMed Pharmaceuticals Inc.,STEMCELL Technologies Inc.,Irvine Scientificand BIOTIME Inc.
Key benefits of the report:
- This study presents the analytical depiction of the global cancer stem cells industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Cancer stem cells market share.
- The current market is quantitatively analysed from 2020 to 2027 to highlight the global cancer stem cells market growth scenario.
Web: https://www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research
0 Comments